Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 732 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Genotyping Clear all
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects

NCT02486406
View directory record Official record
Conditions
Chronic Hepatitis C Infection
Interventions
Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin, Ombitasvir mini tablet, Paritaprevir mini tablet, Ritonavir mini tablet, Dasabuvir mini tablet, Ribavirin solution
Drug
Lead sponsor
AbbVie
Industry
Eligibility
3 Years to 17 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
11
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 3 Interventional

A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD

NCT00469352
View directory record Official record
Conditions
Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
50 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 22, 2011 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 3 Interventional Results available

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

NCT01241760
View directory record Official record
Conditions
Genotype 1 Chronic Hepatitis C, Treatment Naive
Interventions
Ribavirin, Telaprevir, Pegylated interferon alfa-2a
Drug
Lead sponsor
Janssen Infectious Diseases BVBA
Industry
Eligibility
18 Years to 70 Years
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
37
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Oct 21, 2026, 4:01 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

NCT04926818
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Fingolimod, Ofatumumab, Siponimod, Fingolimod placebo, Siponimod placebo, Ofatumumab placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
10 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
6
States / cities
Little Rock, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 2 Interventional Results available

Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816

NCT02468648
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Sofosbuvir, GS-5816
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 21, 2026, 4:01 AM EDT
Active, not recruiting No phase listed Observational

Multicenter Phenotype-Genotype Analysis of Vascular Stains to Optimize Treatment Utilizing Optical Coherence Tomography

NCT04772911
View directory record Official record
Conditions
Vascular Stains
Interventions
Optical Coherence Tomography (OCT)
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Not listed
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Irvine, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 21, 2026, 4:01 AM EDT
Recruiting No phase listed Observational

Detecting HPV DNA in Anal and Cervical Cancers

NCT04857528
View directory record Official record
Conditions
Cervical Cancer, Anal Cancer, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, Uterine Cervical Cancer
Interventions
Radiation Treatment With or Without Chemotherapy, Blood Sample Collection, HPV Genotyping (HPV DNA Test), Testing Archival Tumor Tissue, Physical Exam, Positron Emission Tomography Scan (PET Scan)/ Computed Tomography Scan (CT Scan)
Radiation · Other · Diagnostic Test
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 21, 2026, 4:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pharmacogenomics of Contraception: Genetic Variants and Etonogestrel Pharmacokinetics

NCT03092037
View directory record Official record
Conditions
Contraception
Interventions
Blood draw
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 16, 2022 · Synced Oct 21, 2026, 4:01 AM EDT
Recruiting Phase 1Phase 2 Interventional

RH Genotype Matched RBC Transfusions

NCT04156893
View directory record Official record
Conditions
Sickle Cells Disease
Interventions
Red cell units that are genotype matched at the RHD and RHCE loci
Biological
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Months and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of ABT-072 in Healthy and Hepatitis C Virus Genotype 1-Infected Adults

NCT00752687
View directory record Official record
Conditions
Hepatitis C
Interventions
ABT-072, placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Abbott Park, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 21, 2010 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 4 Interventional Results available

Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients

NCT02781649
View directory record Official record
Conditions
End-Stage Renal Disease, Hepatitis C
Interventions
Zepatier, Ribavirin, Sofosbuvir
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 21, 2026, 4:01 AM EDT
Recruiting Not applicable Interventional

GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care

NCT05391126
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Cancer
Interventions
Irinotecan
Drug
Lead sponsor
Reema A. Patel
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 2 Interventional Results available

A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)

NCT00420784
View directory record Official record
Conditions
Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a, Matching Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
41
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 2 Interventional Results available

Study of SCY-635, Pegasys and Copegus in Hepatitis C

NCT01265511
View directory record Official record
Conditions
Hepatitis C Infection
Interventions
Placebo, SCY-635, Pegasys, Copegus
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
San Francisco, California • Durham, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Not applicable Interventional Results available

Implementing Genomics in Practice (IGNITE): CYP2D6 Genotype-Guided Pain Management in Patients Undergoing Arthroplasty Surgery

NCT03534063
View directory record Official record
Conditions
Pain, Postoperative
Interventions
CYP2D6-guided opioid therapy
Genetic
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Gainesville, Florida • Summerfield, Florida
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 2 Interventional Results available

Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection

NCT01924949
View directory record Official record
Conditions
Hepatitis C
Interventions
LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 3 Interventional Results available

The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE)

NCT00483938
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Pegylated-interferon Alfa-2a, Ribavirin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 2 Interventional Results available

Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care

NCT01359644
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
PSI-7977, Daclatasvir, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
17
States / cities
Coronado, California • San Diego, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2015 · Synced Oct 21, 2026, 4:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

EEG & Behavioral Predictors of Changes in Smoking Trajectories in Young Light Smokers

NCT02129387
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Not listed
Lead sponsor
Southern Illinois University Carbondale
Other
Eligibility
18 Years to 25 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Carbondale, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection

NCT01431898
View directory record Official record
Conditions
Hepatitis C
Interventions
GS-9669 tablets, Placebo to Match GS-9669 tablet
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
10
States / cities
Los Angeles, California • DeLand, Florida • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2012 · Synced Oct 21, 2026, 4:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetics of Ehlers-Danlos Syndrome

NCT03093493
View directory record Official record
Conditions
Genetics Syndrome, Ehlers-Danlos Syndrome
Interventions
Genotyping
Diagnostic Test
Lead sponsor
Boston University
Other
Eligibility
Not listed
Enrollment
334 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs

NCT00004852
View directory record Official record
Conditions
HIV Infections
Interventions
Efavirenz, Lamivudine, Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
46
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Not applicable Interventional

A Placebo-Controlled Study of Physiologic Effects of L-methylfolate in Schizophrenia Patients

NCT01091506
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, L-methylfolate
Other
Lead sponsor
Pamlab, Inc.
Industry
Eligibility
18 Years to 68 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Oct 21, 2026, 4:01 AM EDT
Withdrawn Phase 4 Interventional

Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1

NCT02485080
View directory record Official record
Conditions
PT-NANBH
Interventions
Simeprevir, Sofosbuvir
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 72 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Palo Alto, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 13, 2016 · Synced Oct 21, 2026, 4:01 AM EDT